Related Experiment Video
Updated: Aug 6, 2025

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
Identification of circRNA-miRNA-mRNA regulatory network and its role in cardiac hypertrophy
Ke Gong1, Kai Yang2, Ting Xie1
1Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Central South University, Changsha, P.R. China.
Insights
This study identifies a novel circRNA-miRNA-mRNA network involved in hypertrophic cardiomyopathy (HCM). This network may offer new biomarkers for early screening and predicting prognosis of HCM.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) poses a significant health risk.
- Circular RNAs (circRNAs) and microRNAs (miRNAs) are key players in HCM.
- The role of ceRNA networks in HCM requires further investigation.
Purpose of the Study:
- To investigate the biological activities of ceRNA in HCM.
- To construct a ceRNA network for HCM.
- To identify potential biomarkers and therapeutic targets for HCM.
Main Methods:
- Analyzed Gene Expression Omnibus (GEO) database for differentially expressed RNAs in HCM.
- Predicted circRNA and miRNA targets.
- Constructed a circRNA-miRNA-mRNA ceRNA network.
- Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
- Validated hub genes using quantitative polymerase chain reaction (qPCR).
Main Results:
- Identified a ceRNA network with two differentially expressed circRNAs, two differentially expressed miRNAs, and thirty differentially expressed mRNAs.
- Pathway analysis linked HCM mechanisms to calcium channel release.
- qPCR confirmed differential expression of circRNA, miRNA, and mRNA.
Conclusions:
- A circRNA-miRNA-mRNA network is closely related to HCM progression and outcomes.
- This network may provide novel noninvasive biomarkers for early screening and prognostic prediction of HCM.
- The identified network holds potential as a source of therapeutic targets for HCM.
Background:
Hypertrophic cardiomyopathy (HCM) is a grave hazard to human health. Circular RNA (circRNAs) and micro RNA (miRNAs), which are competitive endogenous RNA, have been shown to play a critical role inHCM pathogenicity. However, to a great extent, the biological activities of ceRNA in HCM pathophysiology and prognosis remain to be investigated.
Materials And Methods:
By analyzing the expression files in the Gene Expression Comprehensive (GEO) database, differentially expressed (DE) circRNAs, miRNAs, and mRNAs in HCM were identified, and the target molecules of circRNAs and miRNAs were predicted. The intersection of the differentially expressed RNA molecules and the expected target was then calculated, and a ceRNA network was subsequently constructed using RNA molecules. Using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, the potential etiology was elucidated. qPCR was used to validate a portion of the hub gene using Angiotensin II to generate a cell hypertrophy model.
Results:
Three large-scale HCM sample datasets were extracted from the GEO database. After crossing these molecules with their expected targets, the circRNA-miRNA-mRNA network had two DEcircRNAs, two DEmiRNAs, and thirty DEmRNAs, compared to normal tissues. Functional enrichment analysis of GO and KEGG demonstrated that many of the HCM pathways and mechanisms were associated with calcium channel release, which is also the primary focus of future research. The qPCR results revealed that circRNA, miRNA, and mRNA expression levels were different. They may include novel noninvasive indicators for the early screening and prognostic prediction of HCM.
Conclusion:
In this study, we hypothesized a circRNA-miRNA-mRNA regulation network that is closely related to the progression and clinical outcomes of HCM and may contain promising biomarkers and treatment targets for HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology

